Compare Amgen, Inc. (AMGN) vs Godaddy Inc (GDDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Godaddy Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Godaddy Inc trades at $88.92 (market cap $11.77B). The key difference: Amgen, Inc. is far larger — about 16.7× Godaddy Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals.
| AMGN | GDDY | |
|---|---|---|
Market Cap | $196.12B | $11.77B |
Sector | Health | Technology |
52-Week High | $388.16 | $169.79 |
52-Week Low | $271.18 | $75.07 |
Enterprise Value | $241.41B | $14.36B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
GoDaddy (GDDY) trades at $88.92, up 1.19% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 63.77% gross margin and 17.32% net margin, though revenue growth has slowed. Analyst consensus is bullish with a $123 price target, but legal investigations pose near-term sentiment risks.
Outlook remains positive based on fundamentals and analyst ratings, but investors should weigh the high ROE and cash flow strength against slowing revenue growth and ongoing legal scrutiny. The stock offers value at a P/E of 14.09, yet legal overhang may limit upside until resolved.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
